儿童免疫性血小板减少症临床病程的生物学分层
本研究纳入147例小于7岁新诊断免疫性血小板减少症(ITP)患儿,随机分为静脉注射免疫球蛋白(IVIg)组或观察组,利用46项临床、基因、免疫表型及血小板自身抗体变量构建生物学风险评分。该评分预测IVIg无持续应答的敏感度为0.91(95%CI 0.80-1.00)、特异度为0.67(95%CI 0.53-0.80),并与观察组1年随访恢复相关。
要点
- 生物学风险评分可预测IVIg后无持续应答,敏感度0.91、特异度0.67
- 评分包含血红蛋白、血小板计数、FcγR IIc基因多态性、IgG抗血小板抗体及前期疫苗接种
- 生物学评分加入预设临床评分可进一步改善对良好ITP病程的区分
核心结论
- 联合临床与生物学分层可改善对儿童ITP病程及IVIg治疗反应的预测。
研究设计与样本
- 多中心随机对照研究二次分析,纳入147例小于7岁新诊断ITP患儿,随机分IVIg组或观察组,评估46项变量。
主要发现
- IVIg组80例中48例(60%)达完全持续应答(血小板≥100×109/L持续至少1个月),32例无应答或仅暂时应答。
- 生物学风险评分预测无持续应答的敏感度为0.91(95%CI 0.80-1.00),特异度为0.67(95%CI 0.53-0.80)。
- 观察组67例中该评分亦与1年随访期间的恢复相关。
- 生物学评分加入预设临床评分后进一步改善了对良好ITP病程的区分。
关键数值与推荐
- 生物学风险评分入选5个变量:血红蛋白、血小板计数、FcγR IIc基因多态性、IgG抗血小板抗体存在、前期疫苗接种。
- 完全持续应答定义为血小板≥100×109/L且持续至少1个月。
临床怎么用
- 对小于7岁新诊断ITP患儿可结合临床与生物学评分预判IVIg应答及病程,辅助治疗决策。
局限性
- 原文摘要未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In childhood immune thrombocytopenia (ITP), an autoimmune bleeding disorder, there is a need for better prediction of individual disease courses and treatment outcomes. OBJECTIVE: To predict the response to intravenous immunoglobulins (IVIg) and ITP disease course using genetic and immune markers. METHODS: Children aged younger than 7 years with newly diagnosed ITP (N = 147) from the Treatment With or Without IVIG for Kids with ITP study were included, which randomized children to an IVIg or observation group. A total of 46 variables were available: clinical characteristics, targeted genotyping, lymphocyte immune phenotyping, and platelet autoantibodies. RESULTS: In the treatment arm, 48/80 children (60%) showed a complete response (platelets ≥100 × 109 /L) that lasted for at least 1 month (complete sustained response [CSR]) and 32 exhibited no or a temporary response (absence of a sustained response [ASR]). For a biological risk score, five variables were selected by regularized logistic regression that predicted ASR vs CSR: (1) hemoglobin; (2) platelet count; (3) genetic polymorphisms of Fc-receptor (FcγR) IIc; (4) the presence of immunoglobulin G (IgG) anti-platelet antibodies; and (5) preceding vaccination. The ASR sensitivity was 0.91 (95% confidence interval, 0.80-1.00) and specificity was 0.67 (95% confidence interval, 0.53-0.80). In the 67 patients of the observation arm, this biological score was also associated with recovery during 1 year of follow-up. The addition of the biological score to a predefined clinical score further improved the discrimination of favorable ITP disease courses. CONCLUSIONS: The prediction of disease courses and IVIg treatment responses in ITP is improved by using both clinical and biological stratification.
引用
- Schmidt DE, Heitink-Pollé KMJ, Mertens B, et al. Biological stratification of clinical disease courses in childhood immune thrombocytopenia. J Thromb Haemost. 2021. PMID: 33386662. doi:10.1111/jth.15232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。